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Abstract 
Background: Multiple options for permanent or long-acting contraception are available, each with adverse effects 
and benefits. People seeking to end their fertility, and their healthcare providers, need a comprehensive comparison 
of methods to support their decision-making. Permanent contraceptive methods should be compared with long-act-
ing methods that have similar effectiveness and lower anticipated adverse effects, such as the levonorgestrel-releas-
ing intrauterine contraception (LNG-IUC). We aimed to understand the comparability of options for people seeking to 
end their fertility, using high-quality studies. We sought studies comparing laparoscopic tubal ligation, hysteroscopic 
tubal occlusion, bilateral salpingectomy, and insertion of the LNG-IUC, for effectiveness, adverse events, tolerability, 
patient recovery, non-contraceptive benefits, and healthcare system costs among females in high resource countries 
seeking to permanently avoid conception.
Methods: We followed PRISMA guidelines, searched EMBASE, Pubmed (Medline), Web of Science, and screened 
retrieved articles to identify additional studies. We extracted data on population, interventions, outcomes, follow-
up, health system costs, and study funding source. We used the Newcastle–Ottawa Scale to assess risk of bias and 
excluded studies with medium–high risk of bias (NOS < 7). Due to considerable heterogeneity, we performed a narra-
tive synthesis.
Results: Our search identified 6,612 articles. RG, BV, BC independently reviewed titles and abstracts for relevance. 
We reviewed the full text of 154 studies, yielding 34 studies which met inclusion criteria. We excluded 10 studies with 
medium–high risk of bias, retaining 24 in our synthesis. Most studies compared hysteroscopic tubal occlusion and/or 
laparoscopic tubal ligation. Most comparisons reported on effectiveness and adverse events; fewer reported tolerabil-
ity, patient recovery, non-contraceptive benefits, and/or healthcare system costs. No comparisons reported accessibil-
ity, eligibility, or follow-up required. We found inconclusive evidence comparing the effectiveness of hysteroscopic 
tubal occlusion to laparoscopic tubal ligation. All studies reported adverse events. All forms of tubal interruption 
reported a protective effect against cancers. Tolerability appeared greater among tubal ligation patients compared to 
hysteroscopic tubal occlusion patients. No high-quality studies included the LNG-IUC.
Conclusions: Studies are needed to directly compare surgical forms of permanent contraception, such as tubal liga-
tion or removal, with alternative options, such as intrauterine contraception to support decision-making.
Systematic review registration: PROSPERO [CRD42016038254].
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Introduction
Permanent contraception is the most common method of 
fertility control worldwide [1, 2]. Globally, nearly one in 
four females in high income countries use either intrau-
terine contraception or female sterilization [3]. Female 
permanent contraceptive methods are the fourth most 
commonly relied upon method for preventing pregnancy 
among people in Canada [4], and the second most com-
mon method in the United States [5]. Female permanent 
contraception is traditionally achieved using laparo-
scopic tubal ligation. However, in the last two decades, 
other methods to achieve permanent contraception have 
emerged including bilateral salpingectomy and the lev-
onorgestrel-releasing intrauterine contraceptive (LNG-
IUC), while Essure™, micro inserts used in hysteroscopic 
tubal occlusion, has been taken off the market in select 
countries [6–8]. In this review, we focus on comparing 
four methods used to achieve long-term or permanent 
contraception including: laparoscopic tubal ligation, hys-
teroscopic tubal occlusion, bilateral salpingectomy, and a 
long-acting contraceptive, the LNG-IUC.
Laparoscopic tubal ligation is traditionally achieved 
with the clipping, coagulation, or other blocking of the 
fallopian tubes to prevent sperm from travelling to an 
ovulated oocyte [2]. Hysteroscopic tubal occlusion is a 
procedure where micro inserts (i.e. Essure™) are placed 
in the fallopian tubes, and held by stainless steel inner 
and nickel-titanium outer coils. These coils encourage 
tissue growth, which after a few months blocks the fal-
lopian tubes [9, 10]. It takes approximately three months 
for occlusion to occur, and during this time a woman is 
required to use alternate contraceptive methods. A post-
procedure confirmation via ultrasound, hysterosalpin-
gogram, or pelvic X-ray is required before a woman can 
discontinue alternative methods and the procedure is 
considered complete [11].
Bilateral salpingectomy is increasingly being consid-
ered as an alternative option to laparoscopic tubal liga-
tion in several high resource countries such as Canada, 
the United States, Australia, and New Zealand [12–14]. 
With emerging evidence that ovarian cancer originates 
in the fallopian tubes [15], one Canadian province saw an 
increased trend in salpingectomy for female sterilization, 
from 0.4% of female sterilization procedures in 2008 to 
33.0% in 2011 [16], with similar increases seen in Texas 
and New York over a similar time period [17]. At a Kaiser 
Permanente Northern California site, interval salpingec-
tomies increased from 1.0 to 78.1% between 2011 and 
2016 [18]. In June 2017, the Society of Obstetricians and 
Gynaecologists of Canada released a committee opinion 
that when counselling females seeking permanent contra-
ception, physicians should discuss the protective benefit 
of tubal ligation against ovarian cancer, and the “fact that 
the removal of the fallopian tube may provide additional 
benefit”  [14] with no additional side-effects over those 
with laparoscopic tubal ligation [15, 19]. In two Markov 
Plain Language Summary 
There are multiple options available to help people end their fertility: each option with accompanying benefits and 
risks. A comprehensive comparison of the benefits and risks of available options is important to support informed 
decision-making. We aimed to understand the comparability of laparoscopic tubal ligation, hysteroscopic tubal occlu-
sion, bilateral salpingectomy, and a long-acting reversible contraceptive, the levonorgestrel-releasing intrauterine 
contraception (LNG-IUC), among females seeking permanent contraception in high resource countries.
We followed PRISMA guidelines for conducting systematic reviews. We assessed for risk of bias using the Newcastle–
Ottawa scale, to ensure that we were including high-quality studies. We found high variability between the included 
articles, so we performed a narrative synthesis.
We identified 6612 articles and reviewed the full text of 154, of which 34 met our inclusion criteria. We further 
excluded 10 studies due to high risk of bias and included 24 articles in our synthesis. Most compared hysteroscopic 
tubal occlusion and/or laparoscopic tubal ligation. No included studies compared LNG-IUC to other methods. Most 
comparisons reported effectiveness and adverse events, with fewer reporting tolerability, patient recovery time, non-
contraceptive benefits, and costs to the healthcare system. We found inconclusive evidence comparing the effective-
ness of hysteroscopic tubal occlusion to laparoscopic tubal ligation. All options reported adverse events, and all forms 
of tubal interruption reported a protective effect against cancers.
There is insufficient research directly comparing surgical forms of permanent contraception, such as tubal ligation 
or removal, with alternative options, such as intrauterine contraception. High-quality studies are needed to support 
informed decision-making.
Keywords: Permanent contraception, Laparoscopic tubal ligation, Hysteroscopic tubal occlusion, Salpingectomy, 
Levonorgestrel intrauterine contraceptive, Systematic review
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simulation models comparing bilateral salpingectomy 
and laparoscopic tubal ligation, bilateral salpingectomy 
was suggested to reduce ovarian cancer risk, contribute 
to additional quality years of life [20], and result in fewer 
ovarian cancer diagnoses [20], and fewer ovarian-cancer 
related deaths [21]; with a mean incremental cost of $152 
per person [20]. Additional decades of follow up after sal-
pingectomy are still needed to understand how closely 
reality will compare to this simulation.
The LNG-IUC is a long-acting reversible contraceptive 
that may be considered as an alternative to permanent 
contraception for females seeking to end their fertility. 
The insertion of the LNG-IUC has efficacy and effec-
tiveness rates similar to tubal ligation [1–3, 5], as after 
insertion, it does not require maintenance. The LNG-
IUC requires re-purchase and re-insertion every 5 or 
more years [22], may cause irregular bleeding [23], and 
in extremely rare cases, the device may migrate and cause 
uterine perforation [24]. However, this option may be 
attractive due to the avoidance of surgery and the faster 
recovery time compared to that required for other meth-
ods [25]. Therefore, with comparable effectiveness, fewer 
anticipated adverse events, and a similar ‘forgettable’ 
nature as available permanent contraceptive methods, 
the LNG-IUC should be considered an option for females 
seeking to end their fertility.
Despite the many options available, we were unable to 
find a guide for clinicians or for people seeking female 
permanent contraception that systematically compares 
available methods according to important outcomes, nor 
any that include comparable long-acting reversible con-
traception. Permanent contraception decision-making 
can be complex, and shared decision-making requires a 
comprehensive review of available options and relevant 
outcomes to make an informed choice that is aligned 
with each patients’ reproductive goals. Ultimately, the 
choice of which contraceptive method to use should be 
based on an informed understanding of not only effec-
tiveness, but also any accompanying potential risks, addi-
tional benefits, tolerability, and recovery time expected 
for the patient.
Objectives
We aimed to understand what is known from high qual-
ity studies about the comparability of permanent meth-
ods of contraception. We included laparoscopic tubal 
ligation, hysteroscopic tubal occlusion, bilateral sal-
pingectomy, and insertion of the LNG-IUC among peo-
ple seeking permanent female contraception in high 
resource countries.
Primary outcomes included:
• Effectiveness at preventing pregnancy
• Adverse events
• Tolerability
• Patient recovery; and
• Non-contraceptive benefits.
Secondary outcomes included:
• Length of procedure
• Costs to the healthcare system
• Eligibility
• Accessibility
• Follow-ups required to ensure completion or for 
safety monitoring.
Thorough definitions of study objectives are explained 
in the systematic review protocol [26].
Methods
We followed PRISMA guidelines [27] for this analysis in 
accordance with the accompanying explanation and elab-
oration paper [28]. The PRISMA checklist is available in 
Additional file 1.
Protocol registration
We pre-specified and previously published [26] objec-
tives and analyses in a protocol registered on PROSPERO 
(CRD42016038254).
Deviations from the protocol
In the previously published protocol, we did not explicitly 
state that we would remove studies which were assessed 
to be at high risk of bias. BC joined the project as an 
additional reviewer, who contributed to screening of the 
titles and abstracts. RG and BV were anticipated to do 
data extraction independently, and to compare results. 
As we will discuss, for this review RG extracted data for 
all included results, with BV extracting data from a sub-
sample, which were compared for accuracy. Finally, in 
our protocol we noted that excluded studies would be 
listed in a table noting exclusion criteria. Instead, we have 
displayed the reasons for exclusion in the PRISMA flow-
chart for ease of presentation.
Eligibility criteria
We included studies that met the following criteria:
• Population comprised of females of reproductive age 
(15–49), without major comorbidities;
• Prospective and retrospective cohort, case–control, 
or randomized control trial methodology;
• The paper was published in a peer reviewed journal 
in English;
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• The analysis took place in high resource countries 
as defined by the World Bank Country and Lending 
groups [29];
• The interventions included comparisons of any two 
or more of: laparoscopic tubal ligation, hysteroscopic 
tubal occlusion, bilateral salpingectomy, or insertion 
of the LNG-IUC, and/or controls;
• The outcomes assessed included at least one of the 
following: effectiveness, adverse events, tolerability, 
non-contraceptive benefits, patient recovery, acces-
sibility, length of the procedure, follow-ups required, 
eligibility, or costs to the healthcare system.
We excluded studies with these characteristics:
• A case study or case series design;
• Conducted outside of high resource countries;
• Interventions included concomitant procedures.
Information sources
We searched EMBASE, Pubmed (Medline), and Web 
of Science using a combination of MeSH terms and key 
words related to hysteroscopic tubal occlusion, lapa-
roscopic tubal ligation, the LNG-IUC, and bilateral sal-
pingectomy. We also reviewed the references of relevant 
articles. We did not set date restrictions.
Search strategy
We downloaded selected articles in Mendeley Desktop 
1.19.3 software (Elsevier, 2008) for further assessment 
and handling, including study selection. We consulted 
librarians to create our search strategy, which is available 
online: http:// med- fom- cart- grac. sites. olt. ubc. ca/ files/ 
2016/ 05/ Search- Strat egies- Libra rian- edit. docx.
The search strategy was built between April and May 
2016. An initial search was performed on May 16th, 
2016. We performed an updated search of the literature, 
using the same search strategy as outlined above, on Jan-
uary 30th, 2019.
Study selection
Three authors (RG, BC, BV) independently reviewed 
titles and abstracts of initial articles based on relevance. 
RG reviewed all identified articles, and BC and BV each 
reviewed a subset of articles. After comparison of articles 
for relevance based on titles and abstracts, RG reviewed 
full text articles for inclusion or exclusion, noting reasons 
for exclusion.
Data collection process
RG created the data extraction form and initially pilot-
tested the form on a randomly selected subset of studies 
to determine comprehensiveness. We extracted data 
from each study that met the inclusion criteria includ-
ing: population, intervention, comparisons, outcomes, 
and study design (PICOS); follow-up period; and funding 
source for the study, where available.
RG extracted data from all relevant articles, and BV 
independently extracted data from a sample of articles. 
We compared the data extraction forms for accuracy. 
Any discrepancies were adjudicated by the senior author 
(WVN).
Data items
We defined all data items, including definitions of the 
variables sought, in detail in our protocol [26].
Risk of bias in individual studies and across studies
We used the Newcastle Ottawa Scale (NOS) to determine 
risk of bias for cohort and case–control studies [30]. We 
assessed risk of bias for each included study, and pre-
sented the results in a table stratified by study design. As 
the GRADE guidelines suggest, in evaluating a large body 
of evidence, it is important to consider risk of bias across 
outcomes. Where an outcome is reporting data from 
studies that are at high risk of bias and at low risk of bias, 
authors may consider synthesizing only those at low risk 
of bias [31]. Therefore, we excluded any articles assessed 
to be at medium–high risk of bias (NOS score < 7).
We assessed the cumulative risk of bias based on the 
risk of bias found in individual studies, along with careful 
consideration of any outcome reporting bias, incomplete 
study data, or overall quality of the evidence presented 
and synthesized.
Synthesis of results
We aimed to perform a network meta-analysis, but het-
erogeneity was assessed as substantial  (I2 ≥ 80%), with 
wide variability in outcome reporting that precluded a 
valid pooling of results. Therefore, we undertook a nar-
rative synthesis in accordance with the guidelines of 
the Cochrane Consumers and Communication Review 
Group [32], by using text to summarize the overall effects 
and variations in studies, and synthesis across included 
studies to identify the patterns and interpretations of 
overall findings [33]. First, we summarized the main out-
comes and effects for each study and grouped by inter-
vention comparison and outcome. Next, we assessed 
differences to explain the patterns of effect, by consider-
ing variability in the study designs, in populations and 
settings, and the outcome measures used [32]. We organ-
ized the final narrative synthesis by outcome, describing 
the similarities, differences, and patterns of results.
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Results
Study selection
Figure  1 details our study selection process, including 
reasons for exclusion, following PRISMA guidelines [27]. 
Our database search of EMBASE, Pubmed (Medline), 
and Web of Science revealed 6,826 documents, and we 
identified an additional 25 documents screening refer-
ences of relevant articles. After we excluded duplicates 
(239), RG, BC, BV reviewed titles and abstracts based on 
relevance. RG reviewed all 6,612, and BC and BV inde-
pendently reviewed 1,647 and 5,088 studies respectively. 
Of these, we excluded 6,458 because they did not meet 
the inclusion criteria. RG reviewed the full text of the 
remaining 154 studies. BV reviewed 30 full text studies 
and compared them with the relevant articles assessed by 
RG to check for accuracy. We extracted data and assessed 
risk of bias for 34 studies. We found high risk of bias in 
10 studies, leaving a total of 24 studies included in the 
narrative synthesis.
Study characteristics
Included studies compared laparoscopic tubal ligation vs. 
control (n = 2), hysteroscopic tubal occlusion vs. laparo-
scopic tubal ligation (n = 12), laparoscopic tubal ligation 
vs. bilateral salpingectomy (n = 6), laparoscopic tubal 
ligation vs. bilateral salpingectomy vs. control (n = 3), 
hysteroscopic tubal occlusion vs. bilateral salpingec-
tomy vs. laparoscopic tubal ligation (n = 1). Our search 
revealed only one study which included outcomes with 
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Page 6 of 18Gormley et al. Reprod Health          (2021) 18:154 
the LNG-IUC, however it was excluded due to high risk 
of bias.
People who had severe comorbidities were excluded. 
All studies were pairwise comparisons of females of 
reproductive age, who underwent an interval contra-
ceptive procedure (at a time not related to a pregnancy) 
including either laparoscopic tubal ligation, hystero-
scopic tubal occlusion, bilateral salpingectomy, or were 
selected as a control comparison.
The characteristics and results of all included studies 
can be found in Table 1. Six studies compared effective-
ness [34–39]; 15 assessed adverse effects [17, 18, 34, 35, 
38–48]; three compared patient recovery  [18, 35, 44]; 
five compared non-contraceptive benefits, primarily 
the reduction of cancer risk [43, 49–52]; six compared 
tolerability [34, 35, 37–39, 52]; four compared costs 
to the healthcare system;  [38, 53–55] and seven com-
pared length of procedures [17, 18, 38, 44, 47, 48, 55]. 
No included studies compared accessibility, eligibility, or 
follow-up required. The majority of studies (n = 20) were 
observational cohorts, and the rest were case–control 
studies (n = 4). The studies were conducted in the United 
States (n = 13), Canada (n = 2), the UK (n = 2), France 
(n = 2), Denmark (n = 1), Spain (n = 1), Sweden (n = 1), 
Finland (n = 1), and Australia (n = 1). All included stud-
ies were published between 2003 and 2019. Enrolment of 
females of reproductive age (15–49) occurred between 
1966 and 2016, with significant variations in follow-up 
ranging from 2 weeks to 44 years.
Risk of bias within studies
We excluded studies where risk of bias was determined to 
be medium to high (NOS 0–6) in at least one domain of 
assessment of risk, largely due to the observational study 
designs, non-random allocation of interventions, and dif-
ferences in baseline characteristics between comparator 
groups. Our assessment of risk of bias for each study can 
be found in Additional file 2.
Results of individual studies
Results of individual studies can be found in Table 1.
Narrative synthesis of results
Effectiveness
Six studies reported the rate of pregnancy, all of which 
were cohort studies comparing hysteroscopic tubal occlu-
sion and laparoscopic tubal ligation [34–39]. Among the 
included studies, there was a wide range of follow-up 
time to assess effectiveness (from 1 year to a maximum 
of 10 years) [34] and significant variance in directionality 
and strength of the outcome; this likely explains the con-
siderable heterogeneity observed.
Three analyses found no significant difference in the 
risk or reported number of unintended pregnancies 
between laparoscopic tubal ligation and hysteroscopic 
tubal occlusion [34, 37, 38]. A retrospective cohort in 
the United States found that the cumulative rate of 
pregnancy was 1.02 pregnancies per 100 person years 
after hysteroscopic tubal occlusion and 0.88 pregnan-
cies per 100 person years after laparoscopic tubal liga-
tion (p = 0.003). Patients who underwent hysteroscopic 
tubal occlusion were at 1.2 times higher risk of becom-
ing pregnant compared to those who underwent laparo-
scopic tubal ligation [aHR 1.20 (95% confidence interval 
1.09–1.33)]. [39].
Two studies, both conducted in France, found a higher 
risk of pregnancy among laparoscopic tubal ligation than 
hysteroscopic tubal occlusion [35, 36]; however in one 
study, this difference was only significant at 1 year [aHR 
0.70 (0.53–0.92)], but not at 3 years [aHR 1.04 (0.83–
1.30)] [35].
Adverse effects
Fifteen studies assessed adverse effects. Results are 
organized by comparison: six compared hysteroscopic 
tubal occlusion and laparoscopic tubal ligation [34, 35, 
38–41], two compared laparoscopic tubal ligation and a 
control [42, 43], five compared laparoscopic tubal ligation 
and bilateral salpingectomy [17, 18, 44, 45, 48], one com-
pared hysteroscopic tubal occlusion, laparoscopic tubal 
ligation, and bilateral salpingectomy with controls [46], 
and one compared bilateral salpingectomy with laparo-
scopic tubal ligation and with historical matched controls 
[47].
Hysteroscopic tubal occlusion vs. laparoscopic tubal liga-
tion Three studies [34, 40, 41] found no statistically 
significant difference in rates of adverse effects including 
abnormal uterine bleeding, pelvic pain, or opioid man-
aged pain between the two interventions, including at 6 
or 12  months post-procedure. A significantly lower risk 
of chronic pelvic pain and risk of hysterectomy was found 
among women undergoing hysteroscopic tubal occlusion 
at 24 months post-procedure [41].
Hysteroscopic tubal occlusion was associated with a 
lower risk of surgical complications than laparoscopic 
tubal ligation [aOR 0.18 (0.14–0.23)] [35] and a lower 
risk of iatrogenic complications after surgery [OR 0.35 
(0.20–0.61)] [38]. Higher rates of gynecological com-
plications were found in hysteroscopic tubal occlu-
sion patients compared to laparoscopic tubal ligation 
patients [35, 39], including menstrual dysfunction [aHR 
1.23 (1.20–1.27)] [39]. However, pelvic pain incidence 
was found to be significantly lower in hysteroscopic 
tubal occlusion patients compared to laparoscopic 
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tubal ligation patients [21.0% compared with 25.6% at 
2 years, aHR 0.83 (0.80–0.85)] [39].
Laparoscopic tubal ligation vs. comparison Compared 
to controls, included studies did not find a statistically 
significant change in menstrual cycle after undergoing 
laparoscopic tubal ligation [42].
One study found an increase in risk for anal cancer 
among those who underwent laparoscopic tubal liga-
tion compared to those who did not [RR 1.34 (1.11–
1.63)]; however, no associations between laparoscopic 
tubal ligation and risk of endometrium, breast, cervix, 
or colorectal cancers, nor all cancers combined, were 
significant [43].
Laparoscopic tubal ligation vs. bilateral salpingec-
tomy Three studies found that there was no significant 
difference when comparing risk of readmission, blood 
transfusion, or intraoperative complications between 
laparoscopic tubal ligation and bilateral salpingectomy 
[17, 18, 44], nor any difference in post-procedure phy-
sician visits for surgical infection or complication [45]. 
No significant differences in complications were found 
when assessing both immediate (2.9% vs. 2.5%, p = 1.0) 
and short-term (within 30 days) adverse events (14.7% vs. 
4.9%, p = 0.51) among people undergoing laparoscopic 
tubal ligation and bilateral salpingectomy, respectively 
[48]. However, there was a higher risk among people 
who underwent bilateral salpingectomy who required 
prescription analgesic use after surgery compared to 
those who underwent laparoscopic tubal ligation [(aOR 
1.21 (1.14–1.29)] [45].
Hysteroscopic tubal occlusion vs. laparoscopic tubal liga-
tion vs. bilateral salpingectomy vs. controls One study 
performed a retrospective cohort study using administra-
tive data to assess risk of ectopic pregnancy among people 
who underwent surgical sterilizations including bilateral 
salpingectomy, laparoscopy with Filshie clip, minilapa-
rotomy, laparotomy, and hysteroscopic tubal occlusion 
using Essure™ compared to an unspecified destruction or 
occlusion of fallopian tubes [46]. Hazard ratios for ectopic 
pregnancy did not remain significant for laparoscopy 
with Filshie clip, minilaparotomy, and laparotomy, and 
there were no ectopic pregnancies reported for bilateral 
salpingectomy nor hysteroscopic tubal occlusion with 
Essure™ [46].
Bilateral salpingectomy vs. tubal ligation vs. historical 
controls When comparing bilateral salpingectomy and 
laparoscopic tubal ligation to historical controls, there 
was no significant difference when comparing estimated 
median blood loss between bilateral salpingectomy (5 ml) 
with laparoscopic tubal ligation current (7 ml, p = 0.18) or 
historical (10 ml, p = 0.31) controls [47].
Patient recovery
Two studies comparing laparoscopic tubal ligation and 
bilateral salpingectomy found no significant difference 
in terms of length of hospital stay, although there was a 
wide variance in reported length between the two studies 
(median of 1.8 h [18] to 1.31 days [44]).
One study found that women who underwent hystero-
scopic tubal occlusion required fewer sick days compared 
to women who underwent laparoscopic tubal ligation at 
1 year (5.90  days vs. 6.50  days, p < 0.001) and at 3 years 
(28.3 vs. 32.3, p < 0.001). [35].
Non‑contraceptive benefits
Five studies measured non-contraceptive benefits, pri-
marily assessing preventative benefits in reducing the 
risk of developing various cancers. Three compared bilat-
eral salpingectomy or laparoscopic tubal ligation against 
controls [49–51], one compared laparoscopic tubal liga-
tion against controls [43], and the last compared hyst-
eroscopic tubal occlusion and laparoscopic tubal ligation 
directly [52]. Two were case–control studies [50, 51] 
while the rest were cohorts using large administrative 
databases [43, 49, 52].
Overall reduction in ovarian cancer risk [RR 0.80 
(0.76–0.85)], peritoneal cancers [RR 0.81 (0.66–0.98)], 
and cancers of the fallopian tube [RR 0.60 (0.37–0.96)] 
was observed in laparoscopic tubal ligation patients when 
compared to matched controls [43].
Both laparoscopic tubal ligation and bilateral sal-
pingectomy had protective effects against cancers when 
compared to a matched control. Both laparoscopic tubal 
ligation [aHR 0.72 (0.64, 0.81)] and salpingectomy [aHR 
0.65 (0.52–0.81)] had protective effects against ovarian 
or tubal cancer compared to females who did not have 
any surgical intervention [49]. A sub-analysis found that 
bilateral salpingectomy had a greater reduction in risk 
than unilateral salpingectomy [aHR 0.35 (0.17–0.73) vs. 
aHR 0.71 (0.56–0.91) respectively], although data dis-
tinguishing laterality was only available up to 1996 [49]. 
Similarly, people who underwent laparoscopic tubal 
ligation or bilateral salpingectomy had reduced odds of 
developing epithelial ovarian cancer ([OR 0.87 (0.78–
0.98)] and [OR 0.58 (0.36–0.95)], respectively) compared 
to matched controls [50].
An age-matched case–control study found that when 
adjusted, a history of any tubal sterilization proved to 
have a statistically non-significant odds ratio of reducing 
the risk of developing epithelial ovarian cancer [OR 0.59 
(0.29–1.17)] compared to matched controls [51]. Further 
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analyses comparing the effect of bilateral salpingectomy 
against matched controls, non-excisional techniques, and 
partial salpingectomy also remained statistically insig-
nificant [OR 0.22 (0.03–1.87)] [51]. Similarly, Mao et al. 
found no difference in the incidences of gynecologic can-
cer [(0.1% vs. 0.1%, HR 2.63 (0.70–9.91)] or other cancers 
[(1.2% vs. 1.3%, HR 1.03 (0.78–1.36)] after initial hystero-
scopic tubal occlusion compared with laparoscopic tubal 
ligation [52].
Tolerability
Nine studies assessed the ability to perform the intended 
method without requiring other procedures to fix the 
procedure due to an unsuccessful first attempt or to 
perform a second procedure to achieve permanent con-
traception. All studies compared the tolerability of hyst-
eroscopic tubal occlusion with laparoscopic tubal ligation 
with a wide variation in follow-up time, from an average 
of 30 days [34] to 7 years. [52].
Six studies found a significantly higher risk of re-oper-
ation among those who underwent hysteroscopic tubal 
occlusion compared to laparoscopic tubal ligation [34, 35, 
37–39, 52], with studies reporting an increased adjusted 
hazard ratio from 2.05 [39], to 3.26 (1  year post-proce-
dure) [35] and tenfold the odds (1 year post-procedure) 
[38]. The increased risk of re-operation remained after a 
3-year follow up [aHR 1.62 (1.51–1.73)] [35].
Accessibility
We did not find an eligible study that systematically 
measured or compared the out-of-pocket costs for the 
procedure, wait times, or the locations where the proce-
dure can be performed.
Secondary objectives
Eligibility
We did not find an eligible study that systematically 
measured or compared eligibility for the procedures.
Follow‑up required
We did not find an eligible study that compared the num-
ber of follow-up visits needed, or required, to ensure that 
the method was completed or for safety monitoring.
Costs to the healthcare system
Four studies measured costs to the healthcare system 
by index cost. All studies compared total costs between 
hysteroscopic tubal occlusion and laparoscopic tubal 
ligation, either reporting the mean or the median index 
costs per patient when undergoing each procedure. 
Three studies found that hysteroscopic tubal occlusion 
was less costly to perform than laparoscopic tubal liga-
tion [53–55], with total costs for hysteroscopic tubal 
occlusion ranging between $1646 [54] and $3964 [53]. 
Median total costs for laparoscopic tubal ligation ranging 
between $2880 [55] and $5163 [53]. One study found that 
total medical and prescription costs ($7093 vs. $7568, 
p < 0.0001) and procedure-related costs ($4971 vs. $5407, 
p < 0.0001) were lower among women who underwent 
hysteroscopic tubal occlusion compared to tubal ligation 
[53]. However, costs related to complications or failures 
were higher with hysteroscopic tubal occlusion com-
pared to laparoscopic tubal ligation ($272 vs. $176) [54]. 
One study found higher total charges for hysteroscopic 
tubal occlusion compared to laparoscopic tubal ligation 
(median $7832 vs. $5068, p < 0.01) [38].
Length of the procedure
Seven studies compared the length of the procedure, with 
four comparing bilateral salpingectomy and laparoscopic 
tubal ligation, two comparing laparoscopic tubal ligation 
and hysteroscopic tubal occlusion, and one comparing 
bilateral salpingectomy with tubal ligation and historical 
controls.
Four studies found that the bilateral salpingectomy 
procedure took significantly longer than laparoscopic 
tubal ligation to complete (3–11 min longer) [17, 18, 44, 
48] Median/mean surgical times ranged between 33 [18] 
and 44 [48] min for bilateral salpingectomy, and between 
30 [18] and 38 [48] min for laparoscopic tubal ligation. 
Overall median operative times were similar between 
bilateral salpingectomy and tubal ligation (study and his-
torical controls) [47].
Laparoscopic tubal ligation procedure took signifi-
cantly longer (means and medians ranging between 27 
and 52  min) than hysteroscopic tubal occlusion (means 
and medians ranging between 18–36 min) [38, 55].
Risk of bias across studies
Overall, the cumulative evidence presented remains 
at low to medium risk of bias. Due to the observational 
study designs used, we found that there were signifi-
cant sociodemographic differences between comparator 
groups that were not able to be adjusted for. Some studies 
did not fully report their patient demographic, leading to 
questions about comparability. With high heterogeneity 
found, our interpretation of evidence must be balanced 
and cautious. Our conclusions focus on comparisons 
between laparoscopic tubal ligation and hysteroscopic 
tubal occlusion, and we described tentative conclusions 
with other comparisons.
Additional analysis
We did not conduct any additional analyses.
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Discussion
Summary of evidence
There is insufficient data to compare available options for 
people seeking female permanent contraception, espe-
cially comparing to the LNG-IUC. Most studies eligi-
ble for our review compared laparoscopic tubal ligation 
to hysteroscopic tubal occlusion using Essure™ micro 
inserts, which is no longer available for use in some juris-
dictions [6–8]. Most comparisons reported on effec-
tiveness and adverse events; fewer reported tolerability, 
patient recovery, non-contraceptive benefits, and/or 
healthcare system costs. No comparisons reported acces-
sibility, eligibility, or follow-up required.
The majority of studies in our review comparing hys-
teroscopic tubal occlusion and laparoscopic tubal liga-
tion did not find a significant difference in effectiveness. 
However, for hysteroscopic tubal occlusion, success of 
effectiveness relied on participants using another form 
of contraception, or abstinence, before tubal occlusion 
could be confirmed with a hysterosalpingogram and 
correct bilateral placements of the micro inserts. Other 
options, including laparoscopic tubal ligation, bilat-
eral salpingectomy, and insertion of the LNG-IUC are 
immediately effective. Although studies that assessed 
the effectiveness of the LNG-IUC were not included, 
other reviews have demonstrated the high efficacy of this 
method, with a cumulative pregnancy rate of 0.5 per 100 
users [23], which appears comparable to laparoscopic 
tubal ligation [56].
Non-contraceptive benefits primarily looked at pro-
tective effects against various types of cancers. While 
the magnitude of the protective effect differed between 
methods of permanent contraception, it appears that 
undergoing some form of tubal interruption—whether 
it be occlusion, ligation, or removal—has a protective 
effect against several types of gynecologic cancers. In 
separate reviews, the LNG-IUC is also suggested to have 
protective effects against gynecological cancers [57], as 
well as menorrhagia, endometriosis, adenomyosis, and 
fibroids [23]. Longer term cohort studies will be required 
to effectively compare these protective effects among all 
available options for female permanent or long acting 
contraception.
All options for female permanent have risks of adverse 
effects; however, our review did not find significant dif-
ferences in opioid managed pain, pelvic pain, menstrual 
dysfunction, or intraoperative complications when com-
paring surgical methods and/or controls. One study 
found that hysteroscopic tubal occlusion patients had a 
lower risk of post-procedure hysterectomy 24-months 
post-procedure [41], but the strength of the evidence is 
diminished with potential bias in funding from Bayer, 
the company that created the Essure™ device. Multiple 
studies have found an association between an increased 
risk of anal cancer and a history of laparoscopic tubal 
ligation [43, 58]. Although we did not find articles assess-
ing adverse events of the LNG-IUC to include in our 
review, previous studies found minimal adverse effects, 
with some attributed to the device itself such as dysmen-
orrhea or irregular bleeding, or to the levonorgestrel such 
as weight gain [23]; although there is conflicting evidence 
with weight gain due to levonorgestrel [59]. More serious 
complications, such as uterine perforation, are found to 
occur rarely (estimated 2.6 per 1000 insertions) [24]. A 
systematic review comparing complication rates between 
laparoscopic tubal ligation and bilateral salpingectomy 
for sterilization found no significant differences in blood 
loss, perioperative complications, or rehospitalizations 
[60]. Upcoming research comparing salpingectomy and 
tubal ligation found no difference in time to first physi-
cian visit related to menopause between patients [61].
Laparoscopic tubal ligation was found to be more tol-
erable than hysteroscopic tubal occlusion using Essure™ 
micro inserts, with patients undergoing hysteroscopic 
tubal occlusion requiring higher rates of re-operation to 
complete or to fix the previous contraceptive method [34, 
35, 37–39, 52]. Although not included within our review, 
separate research suggests high tolerability among LNG-
IUC users, including nulliparous females [62]. Spontane-
ous expulsion of the LNG-IUC is uncommon, with an 
overall crude incidence of 9.6% [63]. Spontaneous expul-
sion is higher in patients with adenomyosis, uterine leio-
myoma, heavy menstrual bleeding, and dysmenorrhea 
[63]. Premature removal of the LNG-IUC has been found 
to be associated with excessive bleeding, pelvic infec-
tions, pain, depression, and recurrent infections; however 
even in the reported study, continuation rates, especially 
among older cohorts, were high [64].
Patient recovery was assessed by length of hospital 
stay between salpingectomy and tubal ligation, where 
no significant difference was found. Patients undergoing 
laparoscopic tubal ligation reported more sick days at 1 
and 3  year follow ups compared to hysteroscopic tubal 
ligation [35]. Considerations including patient satisfac-
tion, time to return to work, and other factors need to be 
explored further. Separate reviews have found have high 
patient satisfaction after the insertion of the LNG-IUC, 
and an almost immediate recovery time [65–67].
Lastly, we considered costs to the healthcare system. 
While three out of four studies assessing hysteroscopic 
tubal occlusion and laparoscopic tubal ligation found that 
hysteroscopic tubal occlusion was significantly less costly 
to perform than laparoscopic tubal ligation [53–55], costs 
related to complications or failures were higher after 
hysteroscopic tubal occlusion [54]. Costs to the health-
care system also should balance preventative costs, such 
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as savings per life-year gained with prevention of can-
cer cases. No studies calculated preventative cost-sav-
ings accompanying non-contraceptive benefits in each 
method, despite evidence that laparoscopic tubal liga-
tion [43, 50, 51], salpingectomy [49, 50], and the LNG-
IUC [68] provide potential cancer risk reduction. Three 
Markov models predicted significant cost-effectiveness 
when bilateral salpingectomy is employed in place of lap-
aroscopic tubal ligation in terms of ovarian cancer pre-
vention and life-years gained [20, 21, 69]. Future patient 
cohort studies will be needed to determine savings real-
ized in practice.
Implications
People seeking to end their fertility need to be able to 
make an informed decision on the range of available 
options with their healthcare providers. However, there is 
insufficient evidence to compare surgical options, such as 
tubal ligation or bilateral salpingectomy, with other non-
surgical options such as intrauterine contraception that 
offer similar effectiveness. Beyond ending fertility, other 
factors that will influence and inform a person’s choice 
for what method is best for them. To make a rigorous 
comparison, there is a need for high-quality research to 
be performed with a broader range of options.
Limitations
We found significant heterogeneity between the included 
articles. This high heterogeneity is likely driven by 
their methodological diversity and observational study 
designs, which did not allow for randomized allocation 
of participants. Therefore, significant differences in study 
population likely existed between the different interven-
tion types, such as age, socioeconomic status, or underly-
ing health conditions that were not excluded as a major 
comorbidity. Follow-up times varied widely between 
the included studies, with some only allotting minimal 
weeks for follow-up time, which biases individual stud-
ies by not allowing for an accurate assessment of possible 
outcomes. Outcomes may thus be attributable to base-
line differences and although associated with the inter-
ventions, may not necessarily be causally linked to the 
interventions.
Secondly, due to high heterogeneity, we were not able 
to complete a network meta-analysis and instead per-
formed a narrative synthesis of results. Limitations to 
narrative synthesis include the potential biasing of results 
by overemphasizing the outcomes of particular stud-
ies, and the inability to objectively compare the different 
options available.
Thirdly, results primarily focused on findings compar-
ing laparoscopic tubal ligation and/or hysteroscopic tubal 
occlusion, with 10 out of 24 studies assessing bilateral 
salpingectomy and no articles assessing the LNG-IUC. 
Therefore, results of studies focusing on bilateral sal-
pingectomy may be overemphasized as our outcomes are 
based on less available evidence.
Full text review was primarily done by one author, with 
a select subsection checked for accuracy. Therefore, it is 
possible that errors in data collection were made. Finally, 
as our study did not include grey literature, we must con-
sider publication bias which overestimates significant 
results within studies.
Conclusions
High quality studies that compare traditional forms of 
permanent contraception, such as the laparoscopic tubal 
ligation, with newer alternative methods, are urgently 
needed to provide evidence for informed decision-mak-
ing for all options available to people seeking permanent 
female contraception.
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